



DIRECTORATE FOR PHARMACEUTICAL POLICY AND MONITORING
Strategy and Sustainability Division
Ministry for Social Policy

12/10/2009

DH Circular No.256/2009
DH 3983/2009

Attention all Consultants
Medical Officers
Pharmacists
Nursing Officers

Correction of DH Circular No.252/2009

Re : Zoledronic Acid preparations

Kindly note that there are **two** parenteral preparations of zoledronic acid available on the Government Formulary for different clinical indications, in line with the SPCs for both products. Zoledronic acid 5mg injections (Aclasta®) for the treatment of Paget's Disease can be prescribed by Consultant Rheumatologists as per protocol number 229, whilst zoledronic acid 4mg injections (Zometa®) prescribed by Consultants, will be reserved for oncology patients suffering from malignant hypercalcaemia, bone secondaries and myeloma with osteolysis as per protocol number 228.

The zoledronic acid preparations will in part, replace the use of disodium pamidronate injections for the above mentioned indications. Hence the protocol for pamidronate has also been amended.

The protocols are hereby attached for ease of reference.

For your attention please.

Regards,

Dr N Azzopardi Muscat
Director General SS